P.146 Characterising the molecular consequences of LMNA-related congenital muscular dystrophy in patient myoblasts
(2022)
Journal Article
Storey, E., Holt, I., Owen, S., Synowsky, S., Shirran, S., Morris, G., & Fuller, H. (2022). P.146 Characterising the molecular consequences of LMNA-related congenital muscular dystrophy in patient myoblasts. Neuromuscular Disorders, 32, S108. https://doi.org/10.1016/j.nmd.2022.07.274
Outputs (3)
A Meta-summary and Bioinformatic Analysis Identified Interleukin 6 as a Master Regulator of COVID-19 Severity Biomarkers (2022)
Journal Article
Ghanem, M., Owen, S., Mohamed, A., & Fuller, H. (2022). A Meta-summary and Bioinformatic Analysis Identified Interleukin 6 as a Master Regulator of COVID-19 Severity Biomarkers. Cytokine, 159, Article 156011. https://doi.org/10.1016/j.cyto.2022.156011With the rising demand for improved COVID-19 disease monitoring and prognostic markers, studies have aimed to identify biomarkers using a range of screening methods. However, the selection of biomarkers for validation from large datasets may result i... Read More about A Meta-summary and Bioinformatic Analysis Identified Interleukin 6 as a Master Regulator of COVID-19 Severity Biomarkers.
The proteome signatures of fibroblasts from patients with severe, intermediate and mild spinal muscular atrophy show limited overlap (2022)
Journal Article
Owen, S., Kline, R., Synowsky, S., Shirran, S., Sillence, K., Claus, P., …Holt, I. (2022). The proteome signatures of fibroblasts from patients with severe, intermediate and mild spinal muscular atrophy show limited overlap. Cells, https://doi.org/10.3390/cells11172624Most research to characterise the molecular consequences of spinal muscular atrophy (SMA) have focused on SMA I. Here, proteomic profiling of skin fibroblasts from severe (SMA I), intermediate (SMA II), and mild (SMA III) patients, alongside age-matc... Read More about The proteome signatures of fibroblasts from patients with severe, intermediate and mild spinal muscular atrophy show limited overlap.